The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; none of the 26 sources its claims cite is checked for support yet.
Tadalafil pharmacokinetics in healthy subjects
Open accessAbstract
Aims: To characterize tadalafil plasma pharmacokinetics in healthy subjects following single and multiple doses. Methods: Noncompartmental parameters were calculated for healthy subjects receiving a single 2.5–20‐mg tadalafil dose in 13 clinical pharmacology studies. An integrated statistical analysis of results in 237 subjects provided global averages and an assessment of effects of body mass index (BMI), age, gender and smoking status. Diurnal variation, food effects and proportionality of exposure to dose were analysed in three studies. Multiple‐dose pharmacokinetics were evaluated in a separate study in which parallel groups of 15 subjects received 10 or 20 mg tadalafil once daily for 10 days. Results: Tadalafil was absorbed rapidly with mean Cmax (378 µg l−1 for 20 mg) observed at 2 h; thereafter, concentrations declined nearly monoexponentially with a mean (5th, 95th percentiles) t1/2 of 17.5 (11.5, 29.6) hours. Mean oral clearance (CL/F) was 2.48 (1.35, 4.35) l h−1 and apparent volume of distribution (Vz/F) was 62.6 (39.5, 92.1) l. No clinically meaningful effect of BMI, age, gender or smoking was identified. Exposure was not substantially affected by time of dosing. Food had negligible effects on bioavailability as assessed by 90% confidence intervals for Cmax and AUC mean ratios. Parameters were proportional to dose, indicating that doubling the dose doubled exposure. Steady state was attained by day 5 following once‐daily administration, and accumulation (1.6‐fold) was consistent with the t 1/2. Conclusions: Tadalafil pharmacokinetics are linear with respect to dose and time, and are not affected by food. Systemic clearance is low relative to other phosphodiesterase 5 inhibitors.
Overview
CoChat Summary
TL;DR
Tadalafil pharmacokinetics in healthy subjects are linear with respect to dose and time, with low oral clearance and a prolonged half-life. Food has negligible effect, and once-daily dosing reaches steady state by day 5 with approximately 1.6-fold accumulation.
Key findings
- After a single 20-mg dose, mean Cmax was 378 µg l⁻¹ at median tmax 2 h; mean t₁/₂ was 17.5 h (5th, 95th percentiles 11.5, 29.6), CL/F was 2.48 l h⁻¹ (1.35, 4.35), and Vz/F was 62.6 l (39.5, 92.1).
- Exposure was proportional to dose: doubling the dose increased AUC by 1.96-fold (1.90, 2.02), with β = 0.97 (0.93, 1.01); Cmax increased slightly less than proportionally, by 1.84-fold (1.77, 1.91).
- Food had negligible effect: fed/fasted geometric mean ratios were 1.08 (1.02, 1.15) for AUC and 1.16 (1.07, 1.26) for Cmax, within prespecified equivalence limits. Evening/morning ratios were 0.81 (0.73, 0.90) for AUC and 0.79 (0.71, 0.89) for Cmax, suggesting slightly lower evening bioavailability.
- With 10- or 20-mg once-daily dosing, steady state was attained by day 5; accumulation from day 1 to day 10 was approximately 1.6-fold, and day 10 t₁/₂, CL/F, and Vz/F were similar to single-dose values.
Methods
- Noncompartmental pharmacokinetic parameters were calculated from 13 single-dose clinical pharmacology studies in healthy subjects; an integrated statistical analysis included 237 subjects (186 males), with 45 subjects contributing data from two dosing occasions, and assessed BMI, age, gender, and smoking status.
- Three studies evaluated diurnal effects (12 subjects, 10 mg), definitive food effects (18 subjects, 20 mg fed vs fasted), and dose proportionality (16 subjects, single 2.5-, 5-, 10-, and 20-mg doses in a four-period crossover).
- A separate multiple-dose study randomized 65 healthy subjects to 10 or 20 mg tadalafil once daily for 10 days; 30 subjects participated in the pharmacokinetic assessment. Plasma tadalafil was measured by validated HPLC-MS/MS, and analyses used mixed-effects models, a power model for dose proportionality, and prespecified equivalence confidence intervals.
Limitations
- The paper states that absolute bioavailability of tadalafil following oral dosing has not been determined in any clinical study.
- The paper states that the report does not address populations with erectile dysfunction, hypertension, diabetes, renal insufficiency, hepatic impairment, or CYP3A inducer/inhibitor drug interactions.
- Evident from the text: the integrated analysis was in healthy volunteers who were predominantly Caucasian (228/237) and male (186/237), and several substudies were small (diurnal n = 12; food effect n = 18; dose proportionality n = 16), which limits generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 16 Not checked · 44 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Age, gender and smoking status were also significant covariates; the magnitude of effects is summarized in Table 4.”
§ Tadalafil pharmacokinetics in healthy subjects > Integrated statistical analysis
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant difference between t max values.”
§ Tadalafil pharmacokinetics in healthy subjects > Food effect
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The most frequently reported treatment-emergent adverse events in the study of once-daily dosing for 10 days were: headache (66% of 65 subjects), back pain (60%), myalgia (43%) dyspepsia (19%), nausea (19%), dizziness (17%), fatigue (12%), eye pain (11%) and spontaneous penile erection (11%).”
§ Tadalafil pharmacokinetics in healthy subjects > Safety and tolerability
plainn = 65- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Inspection of the distribution of individual dose-normalized AUC values suggested that exposure was proportional to dose across the eightfold range (2.5-20 mg) (Figure 1).”
- Also stated in: § Dose proportionality · boosted
“Proportionality was concluded since the 95% CI for the slope [ β = 0.97 (0.93, 1.01)] for regression of ln(AUC) on ln(dose) was completely contained within the prespecified equivalence interval.”
§ Tadalafil pharmacokinetics in healthy subjects > Dose proportionality
boostedstates an associationn = 16- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Dose proportionality · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean oral clearance (CL/F) was 2.48 (1.35, 4.35) l h -1”
§ Tadalafil pharmacokinetics in healthy subjects > Abstract
plainn = 237- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 60 claims and every source verdict.
- It may state two separate claims as one. 26
- The quote only partly states this claim. 2
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, at steady-state concentration, the daily exposure is 1.6-fold greater than the same dose taken intermittently (Forgue et al 2006).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Forgue et al 2006
In the citing paper
“The 17.5 hour half-life of tadalafil lends itself to daily dosing because steady-state plasma concentrations are attained within five days of initiating daily dosing (Forgue et al 2006).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Forgue et al 2006
In the citing paper
“Previous bioequivalence clinical trials reported no differences in tadalafil pharmacokinetics between fed and fasted conditions [44,45].”
From Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride (2023) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Tadalafil pharmacokinetics in healthy subjects > Discussion
“Rate and extent of tadalafil absorption in the morning were slightly lower than in the evening.”
§ Tadalafil pharmacokinetics in healthy subjects > Morning vs. evening administration
“The evening/morning ratio (90% CI) of LS means was 0.81 (0.73, 0.90) for AUC and 0.79 (0.71, 0.89) for C max , suggesting slightly lower bioavailability in the evening.”
Citations
Cites
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,341
Introduction to Linear Regression Analysis.
Assunção, R., Sampson, P. D., Montgomery, D. C., & Peck, E. A. (1993) · Journal of the American Statistical Association · doi:10.2307/2290746 · Cited by 5,389
Nonparametrics: Statistical Methods Based on Ranks.
Beaver, R. J., & Lehmann, E. L. (1976) · Biometrics · doi:10.2307/2529529 · Cited by 2,064
Statistics with Confidence: Confidence Intervals and Statistical Guidelines.
JOLLIFFE, F. R., Gardner, M. J., & Altman, D. G. (1990) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.2307/2982808 · Cited by 1,319
Lue, T. F. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422407 · Cited by 1,252
Introduction to Linear Regression Analysis
Porter, D. R., Montgomery, D. C., & Peck, E. A. (1993) · Technometrics · doi:10.2307/1269673 · Cited by 974
The log transformation is special
Keene, O. N. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140810 · Cited by 498
Brock, G. B., McMahon, C. G., Chen, K. K., Costigan, T., Shen, W., Watkins, V., Anglin, G., & Whitaker, S. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64442-4 · Cited by 421
Nichols, D. J., Muirhead, G. J., & Harness, J. A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.00027.x · Cited by 358
Confidence Interval Criteria for Assessment of Dose Proportionality
Smith, B. P., Vandenhende, F. R., DeSante, K. A., Farid, N. A., Welch, P. A., Callaghan, J. T., & Forgue, S. T. (2000) · Pharmaceutical Research · doi:10.1023/a:1026451721686 · Cited by 356
Self-citation
Research works printed but not linked: 5
- Ring BJ, 2004, Identification of the human cytochrome P450 (CYP) responsible for the formation of the major oxidative metabolite of tadalafil (Cialis), Drug Metab Rev, 36, 70
- Phillips DL, 2004, Metabolism and excretion of tadalafil in healthy men after oral administration of 100 mg [14C]‐tadalafil, The AAPS J, 6
- Patterson B, 2001, Dose‐normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers, Int J Impotence Res, 13, S32
- 2002, Guidance for Industry, Food‐Effect Bioavailability and Fed Bioequivalence Studies.
- Angulo J, 2001, IC351 enhances nitric oxide‐mediated relaxation of human arterial and trabecular penile smooth muscle, Diabetologia, 44, A295
Cited by
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Hatzimouratidis, K., Amar, E., Eardley, I., Giuliano, F., Hatzichristou, D., Montorsi, F., Vardi, Y., & Wespes, E. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.020 · Cited by 1,223
Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
McVary, K. T., Roehrborn, C. G., Kaminetsky, J. C., Auerbach, S. M., Wachs, B., Young, J. M., Esler, A., Sides, G. D., & Denes, B. S. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.11.037 · Cited by 302
Roehrborn, C. G., McVary, K. T., Elion-Mboussa, A., & Viktrup, L. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.06.079 · Cited by 223
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
García‐Osta, A., Cuadrado‐Tejedor, M., García, C., Oyarzábal, J., & Franco, R. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn3000907 · Cited by 266
Weed, D. T., Vella, J. L., Reis, I. M., De la fuente, A. C., Gomez, C., Sargi, Z., Nazarian, R., Califano, J., Borrello, I., & Serafini, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1711 · Cited by 261
Konstantinos Hatzimouratidis, A., Salonia, A., Adaikan, G. P., Buvat, J., Carrier, S., El-Meliegy, A., McCullough, A., Torres, L. O., & Khera, M. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.01.016 · Cited by 255
Montorsi, F., Brock, G. B., Stolzenburg, J., Mulhall, J. P., Moncada, I., PATEL, H. R. H., Chevallier, D., Krajka, K., Henneges, C., Dickson, R. A., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.09.051 · Cited by 253
SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunction
Porst, H., Burnett, A. L. “., Brock, G. B., Ghanem, H. M., Giuliano, F., Glina, S., Hellstrom, W. J. G., Martín‐Morales, A., Salonia, A., & Sharlip, I. D. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12023 · Cited by 220
Porst, H., Giuliano, F., Glina, S., Ralph, D., Casabé, A. R., Elion-Mboussa, A., Shen, W., & Whitaker, J. S. (2006) · European Urology · doi:10.1016/j.eururo.2006.02.052 · Cited by 152
Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD
García, C., Ricobaraza, A., Pascual‐Lucas, M., Unceta, N., Rico, A. J., Goicolea, M. A., Sallés, J., Lanciego, J. L., Oyarzábal, J., Franco, R., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.052 · Cited by 187
Porst, H., Kim, E. D., Casabé, A. R., Mirone, V. G., Secrest, R. J., Xu, L., Sundin, D. P., & Viktrup, L. (2011) · European Urology · doi:10.1016/j.eururo.2011.08.005 · Cited by 179
Hummel, J., McKendrick, S., Brindley, C., & French, R. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.326 · Cited by 178
Goudie, A. R., Lipworth, B. J., Hopkinson, P., Wei, L., & Struthers, A. D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70013-x · Cited by 143
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Pharmacology and perspectives in erectile dysfunction in man
Mitidieri, E., Cirino, G., Bianca, R. D. D. V., & Sorrentino, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107493 · Cited by 133
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease
Wu, Y., Li, Z., Huang, Y., Wu, D., & Luo, H. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01370 · Cited by 130
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128
Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction
Hatzichristou, D., Gambla, M., Rubio‐Aurioles, E., Buvat, J., Brock, G. B., Spera, G., Rose, L., Lording, D., & Liang, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02338.x · Cited by 99
Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects
Wrishko, R. E., Dingemanse, J., Yu, A., Darstein, C., Phillips, D. L., & Mitchell, M. I. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008315315 · Cited by 118
Self-citationRajfer, J., Aliotta, P. J., Steidle, C. P., Fitch, W. P., Zhao, Y., & Yu, A. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901496 · Cited by 113
Koka, S., Das, A., Zhu, S., Durrant, D., Xi, L., & Kukreja, R. C. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170191 · Cited by 108
Yafi, F. A., Sharlip, I. D., & Becher, E. F. (2017) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.08.001 · Cited by 105
Corona, G., Mondaini, N., Ungar, A., Razzoli, E., Rossi, A., & Fusco, F. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02473.x · Cited by 99
Role of phosphodiesterase 5 in synaptic plasticity and memory
Puzzo, D., Sapienza, S., Arancio, O., & Palmeri, A. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2447 · Cited by 97
Porst, H., McVary, K. T., Montorsi, F., Sutherland, P. D., Elion‐Mboussa, A., Wolka, A. M., & Viktrup, L. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.033 · Cited by 96
Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction
Porst, H., Rajfer, J., Casabé, A., Feldman, R., Ralph, D., Vieiralves, L. F., Esler, A., Wolka, A. M., & Klise, S. R. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.00935.x · Cited by 72
A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy
Victor, R. G., Sweeney, H. L., Finkel, R. S., McDonald, C. M., Byrne, B. J., Eagle, M., Goemans, N., Vandenborne, K., Dubrovsky, A. L., Topaloğlu, H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004570 · Cited by 79
The use of phosphodiesterase 5 inhibitors with concomitant medications
Corona, G., Razzoli, E., Forti, G., & Maggi, M. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03349261 · Cited by 75
Efficacy and Safety of Tadalafil in Men With Erectile Dysfunction Following Spinal Cord Injury
Giuliano, F., Ramos, A. S., Löchner-Ernst, D., POPOLO, G. D., Cruz, N., Leriche, A., Lombardi, G., Reichert, S., Dahl, P., Elion‐Mboussa, A., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.nct70001 · Cited by 73
Tadalafil for the treatment of benign prostatic hyperplasia
Mónica, F. Z., & Nucci, G. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1589452 · Cited by 68
Mao, F., Wang, H., Wei Min, N. I., Zheng, X., Wang, M., Bao, K., Ling, D., Li, X., Xu, Y., Zhang, H., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00345 · Cited by 68
Forgue, S. T., Phillips, D. L., Bedding, A. W., Payne, C. D., Jewell, H., Patterson, B. E., Wrishko, R. E., & Mitchell, M. I. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02726.x · Cited by 67
Self-citationSafety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil
Wrishko, R. E., Sorsaburu, S., Wong, D., Strawbridge, A. B., & McGill, J. M. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01301.x · Cited by 63
Self-citationDahlgren, D., Venczel, M., Ridoux, J.-P., Skjöld, C., Müllertz, A., Holm, R., Augustijns, P., Hellström, P. M., & Lennernäs, H. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.005 · Cited by 62
Rossi, S. S., Anzillotti, L., de la Torre, X., & Botrè, F. (2010) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4568 · Cited by 62
Tuttle, T. R., Mierzwa, M. L., Wells, S. I., Fox, S. R., & Ben‐Jonathan, N. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.024 · Cited by 62
Retinal Effects of 6 Months of Daily Use of Tadalafil or Sildenafil
Cordell, W. H., Maturi, R. K., Costigan, T. M., Marmor, M. F., Weleber, R. G., Coupland, S. G., Danis, R. P., McGettigan, J. W., Antoszyk, A. N., Klise, S., et al. (2009) · Yearbook of Urology · doi:10.1016/s0084-4071(10)79408-2 · Cited by 62
A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma
Farthing, C. A., Farthing, D. E., Koka, S., Larus, T. L., Fakhry, I., Xi, L., Kukreja, R. C., Sica, D. A., & Gehr, T. W. B. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.07.022 · Cited by 60
Angulo, J. C., Cuevas, P., Fernández, A., Fuente, J. M. L., Allona, A., Moncada, I., & de Tejada, I. S. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02821.x · Cited by 59
Ribaudo, G., Ongaro, A., Zagotto, G., Memo, M., & Gianoncelli, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00244 · Cited by 59
Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: From physiology to Alzheimer’s disease
Tropea, M. R., Gulisano, W., Vacanti, V., Arancio, O., Puzzo, D., & Palmeri, A. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.022 · Cited by 55
Demır, E., İnam, R., Özkan, S. A., & Uslu, B. (2014) · Journal of Solid State Electrochemistry · doi:10.1007/s10008-014-2529-5 · Cited by 55
Lawless, M., Caldwell, J. L., Radcliffe, E. J., Smith, C. E. R., Madders, G. W. P., Hutchings, D. C., Woods, L. S., Church, S. J., Unwin, R. D., Kirkwood, G. J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42592-1 · Cited by 55
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
Shindel, A. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s9067 · Cited by 52
Treatment Options for Erectile Dysfunction
Brant, W. O., Bella, A. J., & Lue, T. F. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.02.001 · Cited by 51
Arif, S. A., & Poon, H. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.008 · Cited by 47
Taylor, J., Baldo, O., Storey, A., Cartledge, J. J., & Ian Eardley, C. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08328.x · Cited by 45
Tadalafil for the treatment of pulmonary arterial hypertension
Rosenzweig, E. B. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903413542 · Cited by 44
Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer’s disease
Liu, L., Xu, H., Ding, S., Wang, D., Song, G., & Huang, X. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.09.001 · Cited by 43
Iordache, A. M., Docea, A. O., Bugă, A. M., Zlatian, O. M., Ciurea, M. E., Rogoveanu, O. C., Burada, F., Sosoi, S. S., Mitruţ, R., Mamoulakis, C., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.111038 · Cited by 42
Shindel, A. W. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01447.x · Cited by 42
Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors
Masadeh, M. M., Alzoubi, K. H., Khabour, O. F., & Al-Azzam, S. I. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.11.001 · Cited by 41
The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment
Pauls, M. M. H., Binnie, L. R., Benjamin, P., Betteridge, S., Clarke, B. A., Dhillon, M. K., Ghatala, R., Hainsworth, F. A. H., Howe, F. A., Khan, U., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12559 · Cited by 41
A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition
Fusco, F., Razzoli, E., Imbimbo, C., Rossi, A., Verze, P., & Mirone, V. G. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09244.x · Cited by 40
Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
de Graan, A. M., Loos, W. J., Friberg, L. E., Baker, S. D., van der Bol, J. M., van Doorn, L., Wiemer, E. A. C., van der Holt, B., Verweij, J., & Mathijssen, R. H. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0728 · Cited by 40
Doggrell, S. A. (2006) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901525 · Cited by 40
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
Schwarz, E. R. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6392 · Cited by 40
Effect of Phosphodiesterase Inhibition on Insulin Resistance in Obese Individuals
Ho, J. E., Arora, P., Walford, G. A., Ghorbani, A., Guanaga, D. P., Dhakal, B. P., Nathan, D. I., Buys, E. S., Florez, J. C., Newton‐Cheh, C., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001001 · Cited by 39
Cyclic nucleotide phosphodiesterases as drug targets
Kelly, M. P., Nikolaev, V. O., Gobejishvili, L., Lugnier, C., Heßlinger, C., Nickolaus, P., Kass, D. A., de Vasconcelos, W. P., Fischmeister, R., Brocke, S., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100042 · Cited by 39
Wang, Y., Dong, M., Guan, M., Wu, J., He, Z., Zou, Z., Chen, X., Shi, D., Liang, J., & Zhang, X. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00221 · Cited by 37
Buvat, J., Büttner, H., Konstantinos Hatzimouratidis, A., Vendeira, P., Moncada, I., Boehmer, M., Henneges, C., & Boess, F. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12130 · Cited by 36
Anderson, J. R., Nawarskas, J. J., & Henrie, A. M. (2015) · Core evidence · doi:10.2147/ce.s58457 · Cited by 35
Zimmer, D. P., Shea, C. M., Tobin, J. V., Tchernychev, B., Germano, P., Sykes, K., Banijamali, A. R., Jacobson, S., Bernier, S. G., Sarno, R., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00419 · Cited by 35
Jin, C., Guan, M., Dong, M., Wu, J., He, Z., Chen, X., Shi, D., Ren, J., Shi, G., & Zhang, X. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9805-9 · Cited by 34
Lasaponara, F., Sedigh, O., Pasquale, G., Bosio, A., Rolle, L., Ceruti, C., Timpano, M., Negro, C. L. A., Paradiso, M., Abbona, A., et al. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12038 · Cited by 34
Kubo, M., Umekawa, T., Maekawa, Y. M., Tanaka, H., Nii, M., 村林, 奈., Osato, K., Kamimoto, Y., & Ikeda, T. (2016) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13218 · Cited by 34
Ricardi, U., Gontero, P., Ciammella, P., Badellino, S., Valentino, F., Munoz, F., Guarneri, A., Rondi, N., Moretto, F., Filippi, A. R., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01890.x · Cited by 33
Shabsigh, R., Seftel, A. D., Rosen, R. C., Porst, H., Ahuja, S., Deeley, M. C., Garcia, C. S., & Giuliano, F. (2006) · Urology · doi:10.1016/j.urology.2006.05.009 · Cited by 33
Incrocci, L., Slob, A. K., & Hop, W. C. J. (2007) · Urology · doi:10.1016/j.urology.2007.08.029 · Cited by 22
The Interplay between cGMP and Calcium Signaling in Alzheimer’s Disease
Jehle, A., & Garaschuk, O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137048 · Cited by 31
Jin, Z., Zhang, J., Zhi, H., Hong, B.-Z., Zhang, S., Guo, H., & Li, L. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.03.018 · Cited by 31
Majumder, S., Ghosh, S., Pyne, P., Ghosh, A., Ghosh, D., & Hajra, A. (2021) · The Chemical Record · doi:10.1002/tcr.202100288 · Cited by 30
Takahiro, R., Nakamura, S., Kohno, H., Yoshimura, N., Nakamura, T., Ozawa, S. W., Hirono, K., Ichida, F., & Taguchi, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00566 · Cited by 30
Moncada, I., de Bethencourt, F. R., Lledó-García, E., Otero, J., Turbí, C., Büttner, H., Henneges, C., & Martínez‐Salamanca, J. I. (2014) · World Journal of Urology · doi:10.1007/s00345-014-1377-3 · Cited by 30
Rad, R. T., Dadashzadeh, S., Vatanara, A., Alavi, S., Ghasemian, E., & Mortazavi, S. A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.001 · Cited by 30
Zhou, Z., Chen, H., Wu, J., Wang, J., Zhang, X., Ma, J., & Cui, Y. (2019) · Sexual Medicine · doi:10.1016/j.esxm.2019.06.006 · Cited by 29
Hatzichristou, D. G., Haro, J. M., Martín‐Morales, A., Keitz, A. V., Riley, A. J., Bertsch, J., Belger, M. A., Wolka, A. M., Beardsworth, A., & for the EDOS Group (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01560.x · Cited by 29
Hellstrom, W. J. G., Katz, E., Tan, R., & Rittenberg, D. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s57610 · Cited by 29
Tadalafil may improve cerebral perfusion in small-vessel occlusion stroke—a pilot study
Ölmestig, J. N. E., Marlet, I. R., Hansen, R. H., Rehman, S., Krawcyk, R. S., Rostrup, E., Lambertsen, K. L., & Kruuse, C. R. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa020 · Cited by 28
PATEL, H. R. H., Ilo, D., Shah, N. C., Cuzin, B., Chadwick, D., Andrianne, R., Henneges, C., Barry, J., Hell-Momeni, K., Branicka, J., et al. (2015) · BMC Urology · doi:10.1186/s12894-015-0022-9 · Cited by 27
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment
Grünig, E., Ohnesorge, J., Benjamin, N., Burhenne, J., Enderle, Y., Egenlauf, B., Fischer, C., Harutyunova, S., Huppertz, A., Klose, H. F. E., et al. (2017) · Respiration · doi:10.1159/000470916 · Cited by 27
Tay, E. L., Geok-Mui, M. K., Poh-Hoon, M. C., & Yip, J. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.01.046 · Cited by 27
Ford, J. H., Ye, W., Ayer, D. W., Mi, X., Bhandari, S., Buse, D. C., & Lipton, R. B. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00552-4 · Cited by 26
Pauls, M. M. H., Clarke, N., Trippier, S., Betteridge, S., Howe, F. A., Khan, U., Kruuse, C. R., Madigan, J. B., Moynihan, B., Pereira, A. C., et al. (2017) · Trials · doi:10.1186/s13063-017-1973-9 · Cited by 26
PDE5 inhibitor drugs for use in dementia
Hainsworth, A. H., Arancio, O., Elahi, F. M., Isaacs, J. D., & Cheng, F. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12412 · Cited by 26
Garraffo, R., Lavrut, T., Ferrando, S., Durant, J., Rouyrre, N., MacGregor, T. R., Sabo, J. P., & Dellamonica, P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010379808 · Cited by 25
Patients’ preference in the treatment of erectile dysfunction: a critical review of the literature
Morales, A., Casillas, M., & Turbí, C. (2010) · International Journal of Impotence Research · doi:10.1038/ijir.2010.29 · Cited by 25
Sharlip, I. D., Shumaker, B. P., Hakim, L. S., Goldfischer, E. R., Natanegara, F., & Wong, D. G. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00712.x · Cited by 25
Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors
Mostafa, T. (2016) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2015.12.005 · Cited by 24
Mobarak, D. H., Salah, S., & Ghorab, M. M. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.018 · Cited by 24
Abdel‐Raoof, A. M., Said, R. A. M., Emara, M. S., Abolmagd, E., Abdelzaher, A. M., Hasan, M., & Elsayed, A. O. (2020) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2020.118313 · Cited by 24
Effects of Experimental Hyperlipidemia on the Pharmacokinetics of Tadalafil in Rats
Lee, J. H., Oh, J., & Lee, Y. J. (2012) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j35p59 · Cited by 24
Pappula, N., Kodali, B., & Datla, P. V. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.01.020 · Cited by 24
Nagao, K., Kimoto, Y., Marumo, K., Tsujimura, A., Vail, G. M., Watts, S. D., Ishii, N., & Kamidono, S. (2006) · Urology · doi:10.1016/j.urology.2006.05.001 · Cited by 24
Sabri, M., Zolfi-Gol, A., Ahmadi, A., & Javanmard, S. H. (2015) · Pediatric Cardiology · doi:10.1007/s00246-015-1238-x · Cited by 23
Kim, J. S., McSweeney, J. E., Lee, J., & Ivy, D. D. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000622 · Cited by 23
A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction
Hamzehnejadi, M., Tavakoli, M. R., Abiri, A., Ghasempour, A., Langarizadeh, M. A., & Forootanfar, H. (2022) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2022.02.002 · Cited by 23
El Taieb, M., Hegazy, E., & Ibrahim, A. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.06.009 · Cited by 22
Liu, D., Jiang, J., Zhang, L., Tan, F., Wang, Y., Zhang, D. C., & Hu, P. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2398-8 · Cited by 21
Abd‐AlGhafar, W. N., Aboshabana, R., El-Shaheny, R. N., & Tolba, M. M. (2024) · Luminescence · doi:10.1002/bio.4696 · Cited by 21
Metadata
- Authors
- Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Forgue, S. Thomas
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-12-20
- Volume
- 61
- Issue
- 3
- Pages
- 280-288
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC1885023
- OpenAlex
- W1975119053
- Semantic Scholar
- 702568e16e387fed970d136848a9542c93c3e0c0
- Cited by
- 284
- References
- 26
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 20 · 2023: 17 · 2022: 13 · 2021: 14 · 2020: 17 · 2019: 18 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 11 · 2014: 21 · 2013: 13 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- tadalafil, pharmacokinetics, phosphodiesterase-5 inhibitors, oral bioavailability, food effect, dose proportionality, steady-state pharmacokinetics, body mass index, smoking, age and gender effects, healthy volunteers
- MeSH terms
- Tadalafil, Adolescent, Adult, Aged, Biological Availability, Carbolines, Circadian Rhythm, Dose-Response Relationship, Drug, Drug Administration Schedule, Eating, Female, Humans, Male, Metabolic Clearance Rate, Middle Aged, Phosphodiesterase Inhibitors, Body Mass Index, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-14, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-14 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
